{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '16', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.1.11', 'Calibration of Equipment', '89', '8.2', 'Efficacy/Immunogenicity Assessments', '89', '8.2.1', 'Tumor Scans and Assessment of Disease', '89', '8.2.1.1', 'Initial Tumor Scans', '90', '8.2.1.2', 'Tumor Scans During the Study', '91', '8.2.1.3', 'End of Treatment and Follow-up Tumor Scans', '91', '8.2.1.4', 'Second-course Treatment Tumor Scans', '91', '8.2.1.5', 'RECIST 1.1 Assessment of Disease', '92', '8.2.1.6', 'iRECIST Assessment of Disease', '93', '8.2.1.7', 'Tumor Tissue Collection for PD-L1 Status', '96', '8.2.2', 'Patient-reported Outcomes', '96', '8.3', 'Safety Assessments', '97', '8.3.1', 'Physical Examinations', '97', '8.3.2', 'Vital Signs', '97', '8.3.3', 'Electrocardiograms', '97', '8.3.4', 'Echocardiograms or Multigated Acquisition Scans', '98', '8.3.5', 'Clinical Safety Laboratory Assessments', '98', '8.3.5.1', 'Laboratory Safety Evaluations (Hematology, Chemistry and', 'Urinalysis)', '98', '8.3.5.2', 'Pregnancy Test', '99', '8.4', 'Adverse Events (AEs), Serious Adverse Events (SAEs), and Other', 'Reportable Safety Events', '99', '8.4.1', 'Time Period and Frequency for Collecting AE, SAE, and Other', 'Reportable Safety Event Information', '99', '8.4.2', 'Method of Detecting AEs, SAEs, and Other Reportable Safety Events 102', '8.4.3', 'Follow-up of AE, SAE, and Other Reportable Safety Event Information. 102', '8.4.4', 'Regulatory Reporting Requirements for SAE', '102', '8.4.5', 'Pregnancy and Exposure During Breastfeeding', '102', '8.4.6', 'Disease-related Events and/or Disease-related Outcomes Not Qualifying', 'as AEs or SAEs', '103', '8.4.7', 'Events of Clinical Interest (ECIs)', '103', '8.5', 'Treatment of Overdose', '103', '8.6', 'Pharmacokinetics', '104', '8.7', 'Pharmacodynamics', '104', '8.8', 'Planned Genetic Analysis Sample Collection', '104', '8.9', 'Biomarkers', '104', '8.10', 'Medical Resource Utilization and Health Economics', '105', '8.11', 'Visit Requirements', '105', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '17', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.11.1', 'Screening', '105', '8.11.2', 'Initial Treatment Phase', '105', '8.11.3', 'Second-course Treatment Phase', '106', '8.11.4', 'Discontinued Participants Continuing to be Monitored in the Study', '106', '8.11.5', 'Poststudy', '106', '8.11.5.1', 'Safety Follow-up Visit', '106', '8.11.5.2', 'Efficacy Follow-up Visits', '106', '8.11.5.3', 'Survival Follow-up Assessments', '106', '9', 'STATISTICAL ANALYSIS PLAN', '107', '9.1', 'Statistical Analysis Plan Summary', '107', '9.2', 'Responsibility for Analyses/In-house Blinding', '109', '9.3', 'Hypotheses/Estimation', '109', '9.4', 'Analysis Enppoints', '109', '9.4.1', 'Efficacy Endpoints', '109', '9.4.1.1', 'Primary Endpoints', '109', '9.4.1.2', 'Secondary Endpoints', '109', '9.4.1.3', 'Exploratory Endpoints', '110', '9.4.2', 'Safety Endpoints', '110', '9.4.3', 'Patient-reported Outcome Endpoints', '110', '9.5', 'Analysis Populations', '111', '9.5.1', 'Efficacy Analysis Populations', '111', '9.5.2', 'Safety Analysis Populations', '111', '9.5.3', 'Patient-reported Outcome Analysis Population', '111', '9.5.4', 'Pharmacokinetic Analysis Population', '112', '9.6', 'Statistical Methods', '112', '9.6.1', 'Statistical Methods for Efficacy Analyses', '112', '9.6.1.1', 'Progression-free Survival', '113', '9.6.1.2', 'Overall Survival', '114', '9.6.1.3', 'Objective Response Rate', '115', '9.6.1.4', 'Duration of Response', '115', '9.6.2', 'Statistical Methods for Safety Analyses', '115', '9.6.3', 'Statistical Methods for Patient-reported Outcome Analyses', '117', '9.6.4', 'Demographic and Baseline Characteristics', '118', '9.7', 'Interim Analyses', '118', '9.7.1', 'Safety Interim Analyses', '118', '9.8', 'Multiplicity', '118', '9.9', 'Sample Size and Power Calculations', '118', '9.10', 'Subgroup Analyses', '119', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}